A Mechanism of Acquiring Temozolomide Resistance During Transformation of Atypical Prolactinoma Into Prolactin-Producing Pituitary Carcinoma: Case Report
Authors:
- 1 June 2011
- journal article
- case report
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 68 (6) , E1761-E1767
Abstract
BACKGROUND AND IMPORTANCE:. The case presented here describes the clinical evolution of a pituitary carcinoma from an atypical prolactinoma after temozKeywords
This publication has 26 references indexed in Scilit:
- High incidence of low O6-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's diseaseEuropean Journal of Endocrinology, 2009
- Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapyEuropean Journal of Endocrinology, 2009
- Low O6‐methylguanine‐DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumoursClinical Endocrinology, 2009
- USE OF TEMOZOLOMIDE IN AGGRESSIVE PITUITARY TUMORSNeurosurgery, 2009
- P53 gene mutation in an atypical corticotroph adenoma with Cushing's diseaseClinical Endocrinology, 2009
- Pituitary Carcinoma Presenting with Multiple Metastases: Case ReportJournal of Child Neurology, 2008
- Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide TreatmentClinical Cancer Research, 2007
- Long-term response of pituitary carcinoma to temozolomideJournal of Neurosurgery, 2006
- Antitumour effects of temozolomide in a man with a large, invasive prolactin‐producing pituitary neoplasmClinical Endocrinology, 2006
- Screening for the Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer)New England Journal of Medicine, 2005